Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Blood (2024) 144 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2024-207532

Published: 2024

Journal Articles

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Sumithira Vasu, Lapo Alinari, Nicole Szuminski, Dina Schneider, Nathan Denlinger, Wing Keung Chan, Khalid Parris, Nidhi Sharma, Hillary Bradbury, Beth Daneault, Lynn O'Donnell, Boro Dropulic, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7474–7475.

https://doi.org/10.1182/blood-2022-167340

Published: 2022

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, Nidhi Sharma, Alison R. Walker, Sarah A Wall, James S. Blachly, Greg K. Behbehani, Hannah Choe, Aarohi Thakkar, Robin Nakkula, Ella Troy, Nicole Szuminski, Marcos J.G. de Lima, Lynn O'Donnell, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2021-150750

Published: 2021

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, MDMBBS, Bhavana Bhatnagar, DO, James S. Blachly, MD, Nicole Szuminski, BS, Lynn O'Donnell, PhD, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-139170

Published: 2020